Draft gene therapy guidance marks important step
It’s sort of putting a flag in the ground and saying, ‘This is important,’
at a rare disease event on Tuesday
P
Paul ScribnerPKD Foundation · vice president of community programs and education
On the same topic: Biotech & medicine
More →“Novartis now expects to speak with the FDA about a potential accelerated approval of pelabresib before the end of the year, CEO Vas Narasimhan told investors on a call Tuesday.”
“The industry has gotten more consolidated. Prices are higher than ever. Access is worse than ever.”
“The rising costs are unsustainable for individuals, for businesses, and for the country. What kind of intervention is a different question.”